Drugmaker GSK returns to growth in China after torrid time
LONDON, Oct (HKSE: 3366-OL.HK - news) 26 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) comments on China during third-quarter results:
* CEO Andrew Witty tells analysts GSK is fundamentally back to growth in China
* China business up 24% in third quarter
* Reflects particularly the benefit of wholesaler stocking ahead of a systems upgrade
* Excluding the benefit of wholesaler stocking, sales in China grew around 4%
* GSK's China business has been struggling since bribery scandal in 2013
* GSK has since restructured and refocused its China business
* Overall Q3 results coverage (Reporting by Ben Hirschler)